8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 2, 2026·SEC
Cognition Therapeutics, Inc.(CGTX)Earnings, Financials & Key Ratios
CGTX•NASDAQ
Price updated Jun 19, 2026
AboutCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.Show more
- Revenue$0
- EBITDA-$48M+11.4%
- Net Income-$23M+30.9%
- EPS (Diluted)-0.32+62.4%
- ROE-88.6%+43.6%
CGTX Key Insights
Cognition Therapeutics, Inc. (CGTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 18.5% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 83.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CGTX Price & Volume
Cognition Therapeutics, Inc. (CGTX) stock price & volume — 10-year historical chart
Loading chart...
CGTX Growth Metrics
Cognition Therapeutics, Inc. (CGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM64.76%
Return on Capital
10 Years-242.49%
5 Years-153.96%
3 Years-191.11%
Last Year-178.49%
CGTX Recent Earnings
Cognition Therapeutics, Inc. (CGTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
—
$4M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.02+66.7%
$0.06
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.06+14.3%
$0.07
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.11+8.3%
$0.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.06+16.7% | —vs $4M |
| Q2 2026 | Mar 26, 2026 | $0.02vs $0.06+66.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.06vs $0.07+14.3% | — |
| Q3 2025 | Aug 7, 2025 | $0.11vs $0.12+8.3% | — |
Based on last 12 quarters of dataView full earnings history →
CGTX Peer Comparison
Cognition Therapeutics, Inc. (CGTX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% | |||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare CGTX vs Peers
Cognition Therapeutics, Inc. (CGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGTX Income Statement
Cognition Therapeutics, Inc. (CGTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 81K | 98K | 0 | 235K | 0 | 0 | 0 | 61K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -81K▲ 0% | -98K▼ 21.0% | 0▲ 100.0% | -235K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -61K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -20.99% | 100% | - | 100% | - | - | - |
Operating Expenses | 4.67M | 17.31M | 28.6M | 43.32M | 50.72M | 53.97M | 47.8M | 42.78M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 3.45M | 4.52M | 10.03M | 13.23M | 13.53M | 12.29M | 10.61M | 10.32M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 14.38M | 12.89M | 18.57M | 30.32M | 37.2M | 41.68M | 37.19M | 32.52M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | -13.16M | -98K | 0 | -235K | 0 | 0 | 0 | -61K |
Operating Income | -17.83M▲ 0% | -17.41M▲ 2.4% | -28.6M▼ 64.3% | -43.55M▼ 52.3% | -50.72M▼ 16.5% | -53.97M▼ 6.4% | -47.8M▲ 11.4% | -42.84M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 2.38% | -64.29% | -52.29% | -16.47% | -6.39% | 11.43% | - |
EBITDA | -17.75M | -17.31M | -28.5M | -43.32M | -50.47M | -53.7M | -47.57M | -42.66M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 2.48% | -64.68% | -51.96% | -16.52% | -6.4% | 11.41% | 20.1% |
D&A (Non-Cash Add-back) | 81K | 98K | 93K | 235K | 252K | 266K | 228K | 183K |
EBIT | -3.82M | -6.09M | -10.82M | -21.37M | -25.76M | -33.95M | -23.47M | -15M |
Net Interest Income | 12.14M | 9.1M | 16.55M | 22.19M | 27K | -25K | -13K | -3K |
Interest Income | 13.16M | 10.86M | 17.45M | 22.22M | 27K | 0 | 0 | 0 |
Interest Expense | 1.02M | 1.75M | 893K | 28K | 0 | 25K | 13K | 3K |
Other Income/Expense | 0 | 9.57M | 16.88M | 22.15M | 24.94M | 20M | 24.31M | 19.02M |
Pretax Income | -4.84M▲ 0% | -7.84M▼ 61.9% | -11.72M▼ 49.5% | -21.4M▼ 82.6% | -25.79M▼ 20.5% | -33.97M▼ 31.7% | -23.49M▲ 30.9% | -15.01M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | -22.15M | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 103.54% | 0% | 0% | 0% | 0% |
Net Income | -6.95M▲ 0% | -10.07M▼ 44.9% | -11.72M▼ 16.3% | 757K▲ 106.5% | -25.79M▼ 3506.6% | -33.97M▼ 31.7% | -23.49M▲ 30.9% | -15.01M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -44.86% | -16.32% | 106.46% | -3506.6% | -31.73% | 30.86% | 54.93% |
Net Income (Continuing) | -4.84M | -7.84M | -11.72M | 757K | -25.79M | -33.97M | -23.49M | -15.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.32▲ 0% | -0.55▼ 71.9% | -0.73▼ 32.7% | -0.74▼ 1.4% | -0.86▼ 16.2% | -0.85▲ 1.2% | -0.32▲ 62.4% | -0.17▲ 0% |
EPS Growth % | - | -71.88% | -32.73% | -1.37% | -16.22% | 1.16% | 62.35% | 64.76% |
EPS (Basic) | -0.32 | -0.55 | -0.73 | -0.74 | -0.86 | -0.85 | -0.32 | - |
Diluted Shares Outstanding | 21.94M | 21.94M | 22.23M | 28.99M | 30.03M | 39.73M | 72.77M | 89.19M |
Basic Shares Outstanding | 21.94M | 21.94M | 22.23M | 28.99M | 29.99M | 39.73M | 72.77M | 89.19M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CGTX Balance Sheet
Cognition Therapeutics, Inc. (CGTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.16M | 6.91M | 58.99M | 47.65M | 34.22M | 29.55M | 47.99M | 35.81M |
Cash & Short-Term Investments | 2.89M | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M | 31.13M |
Cash Only | 2.89M | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M | 31.13M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 4.12M | 1.15M | 2.27M | 3.67M | 1.28M | 2.69M | 9.92M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 117K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 527.22 | - | - | - | - | - | - | - |
Other Current Assets | -88K | 23K | 11K | 0 | 3.02M | 0 | 1.26M | 4.68M |
Total Non-Current Assets | 299K | 211K | 145K | 2.78M | 941K | 679K | 399K | 326K |
Property, Plant & Equipment | 299K | 211K | 145K | 1.05M | 941K | 679K | 399K | 326K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 1.73M | 0 | 0 | 0 | 0 |
Total Assets | 7.46M▲ 0% | 7.12M▼ 4.6% | 59.14M▲ 730.7% | 50.42M▼ 14.7% | 35.16M▼ 30.3% | 30.23M▼ 14.0% | 48.39M▲ 60.1% | 36.14M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -4.56% | 730.69% | -14.73% | -30.27% | -14.02% | 60.05% | 128.28% |
Total Current Liabilities | 3.68M | 3.25M | 7.86M | 7.79M | 10.17M | 11.14M | 13.92M | 6.05M |
Accounts Payable | 2.36M | 2M | 4.17M | 3.22M | 3.69M | 1.98M | 1.12M | 3.85M |
Days Payables Outstanding | 10.62K | 7.46K | - | 5K | - | - | - | 9.82K |
Short-Term Debt | 0 | 0 | 0 | 634K | 544K | 279K | 443K | 95K |
Deferred Revenue (Current) | 1.32M | 0 | 753K | 1.7M | 1.7M | 1.07M | 367K | 4.3M |
Other Current Liabilities | -531K | 985K | 2.48M | 870K | 1.17M | 1.53M | 11.99M | 1.89M |
Current Ratio | 1.94x | 2.13x | 7.50x | 6.11x | 3.37x | 2.65x | 3.45x | 5.92x |
Quick Ratio | 1.91x | 2.13x | 7.50x | 6.11x | 3.37x | 2.65x | 3.45x | 5.92x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 62.2M | 72.05M | 0 | 2.38M | 520K | 342K | 195K | 176K |
Long-Term Debt | 6.9M | 12.85M | 0 | 0 | 0 | 0 | 0 | 176K |
Capital Lease Obligations | 0 | 0 | 0 | 695K | 520K | 342K | 195K | 636K |
Deferred Tax Liabilities | 0 | 0 | 0 | -695K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 55.3M | 59.2M | 0 | 695K | 0 | 0 | 0 | 0 |
Total Liabilities | 65.88M | 75.3M | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M | 6.23M |
Total Debt | 6.9M | 12.85M | 0 | 1.48M | 1.24M | 814K | 638K | 271K |
Net Debt | 4.01M | 7.66M | -54.72M | -40.08M | -28.68M | -24.2M | -36.17M | -30.86M |
Debt / Equity | - | - | - | 0.04x | 0.05x | 0.04x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.72x |
Interest Coverage | -3.73x | -3.48x | -12.12x | -763.18x | - | -1357.84x | -1805.69x | -4999.67x |
Total Equity | -58.42M▲ 0% | -68.18M▼ 16.7% | 51.27M▲ 175.2% | 40.25M▼ 21.5% | 24.47M▼ 39.2% | 18.75M▼ 23.4% | 34.27M▲ 82.8% | 29.91M▲ 0% |
Equity Growth % | - | -16.71% | 175.2% | -21.5% | -39.19% | -23.39% | 82.78% | 309.34% |
Book Value per Share | -2.66 | -3.11 | 2.31 | 1.39 | 0.82 | 0.47 | 0.47 | 0.34 |
Total Shareholders' Equity | -58.42M | -68.18M | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M | 29.91M |
Common Stock | 1K | 1K | 22K | 29K | 32K | 60K | 90K | 90K |
Retained Earnings | -58.24M | -68.22M | -94M | -115.4M | -141.19M | -175.16M | -198.65M | -203.22M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -185K | -187K | -198K | -199K | -195K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGTX Cash Flow Statement
Cognition Therapeutics, Inc. (CGTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.1M | -3.43M | -3.63M | -18.53M | -16.02M | -28.47M | -24.59M | -20.25M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -10.81% | -5.77% | -410.41% | 13.57% | -77.76% | 13.65% | 126.64% |
Net Income | -4.84M | -7.84M | -11.72M | -21.4M | -25.79M | -33.97M | -23.49M | -15.01M |
Depreciation & Amortization | 81K | 98K | 93K | 235K | 252K | 266K | 228K | 251K |
Stock-Based Compensation | 361 | 475K | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M | 1.47M |
Deferred Taxes | 238K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 854.64K | 766K | -33K | 0 | 318K | 195K | 41K | -971K |
Working Capital Changes | 570K | 3.07M | 2.84M | -943K | 4.85M | 1.29M | -3.46M | -1.43M |
Change in Receivables | -1.12M | 3M | -1.11M | -1.41M | 2.39M | -1.41M | -7.24M | -5.14M |
Change in Inventory | 1.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 862K | -364K | 2.17M | -1.09M | 0 | 0 | 3.51M | -3.98M |
Cash from Investing | -144K | -10K | -27K | -171K | -147K | -4K | 9K | 9K |
Capital Expenditures | -144K | -10K | -27K | -171K | -147K | -4K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 9K | 9K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 2.79M | 5.76M | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M | 35.04M |
Debt Issued (Net) | 2.83M | 5.72M | -268K | -1.4M | -811K | -739K | -353K | -235K |
Equity Issued (Net) | 0 | 47K | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M | 35.63M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -34K | 0 | 9.25M | 1.62M | 0 | -46K | -164K | -351K |
Net Change in Cash | -508K▲ 0% | 2.3M▲ 552.6% | 49.53M▲ 2054.5% | -13.16M▼ 126.6% | -11.64M▲ 11.5% | -4.91M▲ 57.8% | 11.99M▲ 344.1% | 14.8M▲ 0% |
Free Cash Flow | -3.24M▲ 0% | -3.44M▼ 6.2% | -3.66M▼ 6.2% | -18.7M▼ 411.3% | -16.16M▲ 13.6% | -28.48M▼ 76.2% | -24.59M▲ 13.7% | -20.25M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -6.2% | -6.24% | -411.32% | 13.57% | -76.17% | 13.66% | 34.9% |
FCF per Share | -0.15 | -0.16 | -0.16 | -0.65 | -0.54 | -0.72 | -0.34 | -0.23 |
FCF Conversion (FCF/Net Income) | 0.45x | 0.34x | 0.31x | -24.48x | 0.62x | 0.84x | 1.05x | 1.35x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGTX Key Ratios
Cognition Therapeutics, Inc. (CGTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -22.85% | 1.65% | -79.69% | -157.19% | -88.6% | -55.72% |
Return on Invested Capital (ROIC) | - | - | -19795.91% | - | - | - | 1397.14% |
Debt / Equity | - | - | 0.04x | 0.05x | 0.04x | 0.02x | 0.01x |
Interest Coverage | -3.48x | -12.12x | -763.18x | - | -1357.84x | -1805.69x | -4999.67x |
FCF Conversion | 0.34x | 0.31x | -24.48x | 0.62x | 0.84x | 1.05x | 1.35x |
Related:CGTX Dividend History·CGTX Revenue History·CGTX Price History·CGTX P/E History·CGTX Financial Ratios·CGTX Institutional Holders
CGTX SEC Filings & Documents
Cognition Therapeutics, Inc. (CGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CGTX Frequently Asked Questions
Cognition Therapeutics, Inc. (CGTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cognition Therapeutics, Inc. (CGTX) grew revenue by 0.0% over the past year. Growth has been modest.
Cognition Therapeutics, Inc. (CGTX) reported a net loss of $15.0M for fiscal year 2025.
Dividend & Returns
Cognition Therapeutics, Inc. (CGTX) has a return on equity (ROE) of -88.6%. Negative ROE indicates the company is unprofitable.
Cognition Therapeutics, Inc. (CGTX) had negative free cash flow of $20.3M in fiscal year 2025, likely due to heavy capital investments.